Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436191 | 0.86 | DRD4 (0.43) | DRD4SMN1; SMN2TLR9TLR8TLR7 | |
| SCHEMBL30852188 | 0.83 | KDM4E (0.46) | DRD4SMN1; SMN2OPRM1MEN1KMT2A | |
| SCHEMBL3436370 | 0.79 | DRD4 (0.59) | DRD4OPRM1DRD2DRD3OPRL1 | |
| SCHEMBL3436615 | 0.77 | OPRL1 (0.50) | DRD4SMN1; SMN2OPRM1SCN9ACCNT1 | |
| SCHEMBL3466609 | 0.77 | HSD11B1 (0.44) | KMT2A | |
| SCHEMBL3436297 | 0.77 | KMT2A (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL17229672 | 0.76 | HSD11B1 (0.43) | SMN1; SMN2OPRM1MEN1KMT2AALDH1A1 | |
| SCHEMBL16950778 | 0.75 | ABCB1 (0.51) | ALDH1A1OPRL1 | |
| SCHEMBL4776252 | 0.75 | PTGDR2 (0.44) | DRD4SMN1; SMN2ALDH1A1DRD2DRD3 | |
| SCHEMBL3436380 | 0.75 | DRD4 (0.52) | DRD4OPRM1ALDH1A1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | DRD4 4535/4885SMN1; SMN2 3601/4885TLR9 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.